Nikolaos P Polyzos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/555691/publications.pdf

Version: 2024-02-01

125 papers 5,237 citations

38 h-index 98622 67 g-index

127 all docs

127 docs citations

times ranked

127

4102 citing authors

#	Article	IF	Citations
1	An OHSS-Free Clinic by segmentation of IVF treatment. Human Reproduction, 2011, 26, 2593-2597.	0.4	428
2	A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertility and Sterility, 2016, 105, 1452-1453.	0.5	401
3	Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?. Human Reproduction, 2016, 31, dev316.	0.4	247
4	Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in \hat{A} vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including \hat{a}^4 15,000 women. Fertility and Sterility, 2018, 110, 661-670.e1.	0.5	243
5	Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. Journal of the National Cancer Institute, 2006, 98, 1285-1291.	3.0	242
6	ESHRE guideline: ovarian stimulation for IVF/ICSIâ€. Human Reproduction Open, 2020, 2020, hoaa009.	2.3	205
7	A systematic review of randomized trials forÂtheÂtreatment of poor ovarian responders: isÂthereÂany light at the end of the tunnel?. Fertility and Sterility, 2011, 96, 1058-1061.e7.	0.5	195
8	A fresh look at the freeze-all protocol: a SWOT analysis. Human Reproduction, 2016, 31, 491-497.	0.4	133
9	Effect of periodontal disease treatment during pregnancy on preterm birth incidence: a metaanalysis of randomized trials. American Journal of Obstetrics and Gynecology, 2009, 200, 225-232.	0.7	120
10	Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Breast, 2011, 20, 485-490.	0.9	101
11	Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. Reproductive BioMedicine Online, 2014, 28, 469-474.	1.1	100
12	Vitamin D deficiency and pregnancy rates in women undergoing single embryo, blastocyst stage, transfer (SET) for IVF/ICSI. Human Reproduction, 2014, 29, 2032-2040.	0.4	100
13	Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treatment Reviews, 2010, 36, 69-74.	3.4	97
14	Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Breast Cancer Research and Treatment, 2009, 116, 433-439.	1.1	80
15	Combined Vitamin C and E Supplementation During Pregnancy For Preeclampsia Prevention: A Systematic Review. Obstetrical and Gynecological Survey, 2007, 62, 202-206.	0.2	74
16	Safety of Pregnancy After Primary Breast Carcinoma in Young Women: A Meta-Analysis to Overcome Bias of Healthy Mother Effect Studies. Obstetrical and Gynecological Survey, 2010, 65, 786-793.	0.2	69
17	The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Frontiers in Endocrinology, 2019, 10, 814.	1.5	69
18	Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis. Oncologist, 2013, 18, 353-361.	1.9	67

#	Article	IF	Citations
19	Thyroid autoimmunity, hypothyroidism and ovarian reserve: a cross-sectional study of 5000 women based on age-specific AMH values. Human Reproduction, 2015, 30, 1690-1696.	0.4	65
20	Individualised luteal phase support in artificially prepared frozen embryo transfer cycles based on serum progesterone levels: a prospective cohort study. Human Reproduction, 2021, 36, 1552-1560.	0.4	60
21	Partial Breast Irradiation or Whole Breast Radiotherapy for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Breast Journal, 2010, 16, 245-251.	0.4	59
22	Should we continue to measure endometrial thickness in modern-day medicine? The effect on live birth rates and birth weight. Reproductive BioMedicine Online, 2018, 36, 416-426.	1.1	56
23	Aromatase inhibitors for female infertility: a systematic review of the literature. Reproductive BioMedicine Online, 2009, 19, 456-471.	1.1	55
24	Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data. Human Reproduction, 2016, 31, 2261-2267.	0.4	54
25	Predictors of ovarian response in women treated with corifollitropin alfa for inÂvitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 2013, 100, 430-437.	0.5	52
26	The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study. Human Reproduction, 2017, 32, 208-214.	0.4	52
27	Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women ≥38 years old. Human Reproduction, 2018, 33, 2010-2017.	0.4	52
28	The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation. Frontiers in Endocrinology, 2018, 9, 361.	1.5	52
29	The effect of an immediate frozen embryo transfer following a freeze-all protocol: a retrospective analysis from two centres. Human Reproduction, 2016, 31, 2541-2548.	0.4	50
30	Trends in ectopic pregnancy rates following assisted reproductive technologies in the UK: a 12-year nationwide analysis including 160 000 pregnancies. Human Reproduction, 2016, 31, dev315.	0.4	50
31	Identification of the High-Risk Patient for Ovarian Hyperstimulation Syndrome. Seminars in Reproductive Medicine, 2010, 28, 458-462.	0.5	49
32	Increasing vaginal progesterone gel supplementation after frozen–thawed embryo transfer significantly increases the delivery rate. Reproductive BioMedicine Online, 2013, 26, 133-137.	1.1	47
33	Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reproductive BioMedicine Online, 2018, 37, 163-171.	1.1	47
34	What is the clinical impact of the endometrial receptivity array in PGT-A and oocyte donation cycles?. Journal of Assisted Reproduction and Genetics, 2019, 36, 1901-1908.	1.2	47
35	Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. International Journal of Cancer, 2013, 133, 2245-2252.	2.3	45
36	Financial Relationships in Economic Analyses of Targeted Therapies in Oncology. Journal of Clinical Oncology, 2012, 30, 1316-1320.	0.8	44

#	Article	IF	Citations
37	Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: anÂobservational pilot study. Fertility and Sterility, 2013, 99, 422-426.	0.5	41
38	Vitamin D deficiency and pregnancy rates following frozen–thawed embryo transfer: a prospective cohort study. Human Reproduction, 2016, 31, 1749-1754.	0.4	40
39	Double versus single intrauterine insemination for unexplained infertility: a meta-analysis of randomized trials. Fertility and Sterility, 2010, 94, 1261-1266.	0.5	39
40	Factors associated with serum progesterone concentrations the day before cryopreserved embryo transfer in artificial cycles. Reproductive BioMedicine Online, 2020, 40, 797-804.	1.1	39
41	Safety Issues of Hysteroscopic Surgery. Annals of the New York Academy of Sciences, 2006, 1092, 229-234.	1.8	38
42	Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 279-286.	2.3	38
43	Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reproductive BioMedicine Online, 2012, 24, 272-280.	1.1	38
44	Low progesterone levels on the day before natural cycle frozen embryo transfer are negatively associated with live birth rates. Human Reproduction, 2020, 35, 1623-1629.	0.4	35
45	To delay or not to delay a frozen embryo transfer after a failed fresh embryo transfer attempt?. Fertility and Sterility, 2016, 105, 1202-1207.e1.	0.5	34
46	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Human Reproduction, 2017, 32, 2225-2233.	0.4	34
47	Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecologic Oncology, 2010, 117, 139-145.	0.6	32
48	Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?. Fertility and Sterility, 2008, 89, 278-280.	0.5	31
49	Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2010, 73, 220-227.	2.0	31
50	Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) and Serum Placental Growth Factor (PIGF) as Biomarkers for Ectopic Pregnancy and Missed Abortion. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1444-E1451.	1.8	31
51	Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all†in-depth analysis of genetic predisposition. Journal of Assisted Reproduction and Genetics, 2015, 32, 1063-1068.	1.2	30
52	(Meta)analyze this: Systematic reviews might lose credibility. Nature Medicine, 2012, 18, 1321-1321.	15.2	29
53	Colorectal cancer screening coverage in Greece. PACMeR 02.01 study collaboration. International Journal of Colorectal Disease, 2007, 22, 475-481.	1.0	28
54	Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertility and Sterility, 2010, 94, 2083-2087.	0.5	28

#	Article	IF	CITATIONS
55	ICSI does not offer any benefit over conventional IVF across different ovarian response categories in non-male factor infertility: a European multicenter analysis. Journal of Assisted Reproduction and Genetics, 2019, 36, 2067-2076.	1.2	28
56	The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial. Human Reproduction, 2020, 35, 2808-2818.	0.4	27
57	Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology. Reproductive Sciences, 2018, 25, 980-982.	1.1	25
58	Does the time interval between antimüllerian hormone serum sampling and initiation of ovarianÂstimulation affect its predictive ability in inÂvitro fertilization–intracytoplasmic spermÂinjection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. Fertility and Sterility, 2013, 100, 438-444.	0.5	24
59	Cumulative live birth rates in in-vitro fertilization. Minerva Ginecologica, 2019, 71, 207-210.	0.8	24
60	Effect of ovarian stimulation and oocyte retrieval on reproductive outcome in oocyte donors. Fertility and Sterility, 2012, 97, 1328-1330.	0.5	22
61	Treatment of Unexplained Infertility With Aromatase Inhibitors or Clomiphene Citrate. Obstetrical and Gynecological Survey, 2008, 63, 472-479.	0.2	21
62	Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. Gynecological Endocrinology, 2015, 31, 885-890.	0.7	21
63	The effect of polymorphisms in <i>FSHR</i> and <i>FSHB</i> genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. Human Reproduction, 2021, 36, 1711-1721.	0.4	21
64	Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology—"The king is dead, long live the king!― Fertility and Sterility, 2014, 102, 339-341.	0.5	20
65	The endometrium during and after ovarian hyperstimulation and the role of segmentation of infertility treatment. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 61-75.	2.2	20
66	Does the type of GnRH analogue used, affect live birth rates in women with endometriosis undergoing IVF/ICSI treatment, according to the rAFS stage?. Gynecological Endocrinology, 2018, 34, 884-889.	0.7	18
67	How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus. Reproductive BioMedicine Online, 2019, 38, 118-130.	1.1	18
68	Ovarian stimulation for oocyte donation: a systematic review and meta-analysis. Human Reproduction Update, 2021, 27, 673-696.	5.2	17
69	Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. Drugs, 2020, 80, 973-994.	4.9	17
70	Double versus single homologous intrauterine insemination for male factor infertility: a systematic review and meta-analysis. Asian Journal of Andrology, 2013, 15, 533-538.	0.8	16
71	Prevalence, types and possible factors influencing mosaicism in IVF blastocysts: results from a single setting. Reproductive BioMedicine Online, 2021, 42, 55-65.	1.1	16
72	The Role of Androgen Supplementation in Women With Diminished Ovarian Reserve: Time to Randomize, Not Meta-Analyze. Frontiers in Endocrinology, 2021, 12, 653857.	1.5	16

#	Article	IF	CITATIONS
73	Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. Reproductive BioMedicine Online, 2012, 24, 532-539.	1.1	15
74	Management Strategies for POSEIDON's Group 1. Frontiers in Endocrinology, 2019, 10, 679.	1.5	15
75	SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. Human Reproduction, 2020, 35, 1964-1971.	0.4	15
76	Publication bias in reproductive medicine: from the European Society of Human Reproduction and Embryology annual meeting to publication. Human Reproduction, 2011, 26, 1371-1376.	0.4	14
77	Significantly lower ectopic pregnancy rates after frozen embryo transfer: implications toward segmentation of inÂvitro fertilization treatment. Fertility and Sterility, 2012, 98, 1419-1420.	0.5	14
78	The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF/ICSI cycles. Human Reproduction, 2020, 35, 826-836.	0.4	14
79	Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis. Human Reproduction Open, 2021, 2021, hoaa066.	2.3	14
80	Necessity of appendectomy for mucinous borderline ovarian tumors. Systematic review. Archives of Gynecology and Obstetrics, 2016, 294, 1283-1289.	0.8	13
81	Do ovarian endometriomas affect ovarian response to ovarian stimulation for IVF/ICSI?. Reproductive BioMedicine Online, 2020, 41, 37-43.	1.1	13
82	Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not?. International Journal of Medical Sciences, 2011, 8, 492-500.	1.1	11
83	Corifollitropin α followed by menotropin for poor ovarian responders' trial (COMPORT): a protocol of a multicentre randomised trial. BMJ Open, 2013, 3, e002938.	0.8	11
84	Cancer cachexia: global awareness and guideline implementation on the web. BMJ Supportive and Palliative Care, 2013, 3, 155-160.	0.8	11
85	Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study. Gynecological Endocrinology, 2019, 35, 884-889.	0.7	11
86	Androgen supplementation in assisted reproduction: where are we in 2019?. Current Opinion in Obstetrics and Gynecology, 2019, 31, 188-194.	0.9	11
87	Blastocyst versus cleavage embryo transfer improves cumulative live birth rates, time and cost in oocyte recipients: a randomized controlled trial. Reproductive BioMedicine Online, 2022, 44, 995-1004.	1.1	10
88	Effect of embryo transfer difficulty on live birth rates studied in vitrified–warmed euploid blastocyst transfers. Reproductive BioMedicine Online, 2019, 39, 940-946.	1.1	9
89	The effect of late-follicular phase progesterone elevation on embryo ploidy and cumulative live birth rates. Reproductive BioMedicine Online, 2021, 43, 1063-1069.	1.1	9
90	Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus. Frontiers in Endocrinology, 2021, 12, 797365.	1.5	9

#	Article	IF	Citations
91	Review the â€~peer review'. Reproductive BioMedicine Online, 2017, 35, 747-749.	1.1	8
92	OPTIMIST trial: optimistic evidence?. Human Reproduction, 2018, 33, 983-984.	0.4	8
93	Does LH suppression by progesterone-primed ovarian stimulation compared with GnRH antagonist affect live birth rate among oocyte recipients?. Reproductive BioMedicine Online, 2020, 40, 661-667.	1.1	8
94	Is ovarian response associated with adverse perinatal outcomes in GnRH antagonist IVF/ICSI cycles?. Reproductive BioMedicine Online, 2020, 41, 263-270.	1.1	8
95	Androgens and diminished ovarian reserve: the long road from basic science to clinical implementation. A comprehensive and systematic review with meta-analysis. American Journal of Obstetrics and Gynecology, 2022, 227, 401-413.e18.	0.7	8
96	The performance of the Elecsys \hat{A}^{\otimes} anti-M \tilde{A}^{1} /Allerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reproductive BioMedicine Online, 2020, 41, 29-36.	1.1	7
97	Time-trend of melanoma screening practice by primary care physicians: A meta-regression analysis. Upsala Journal of Medical Sciences, 2009, 114, 32-40.	0.4	6
98	Limited ability of circulating anti-M $\tilde{A}^{1}/4$ llerian hormone to predict dominant follicular recruitment in PCOS women treated with clomiphene citrate: a comparison of two different assays. Gynecological Endocrinology, 2016, 32, 227-230.	0.7	6
99	Food for thought in women's health. The gynecologist: the new European gatekeeper inChlamydia trachomatisinfection. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 1156-1159.	1.3	5
100	How do you solve the problem of recurrent miscarriage?. Reproductive BioMedicine Online, 2009, 19, 296-297.	1.1	4
101	Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapy. Medical Oncology, 2010, 27, 1309-1313.	1.2	4
102	Linking back-to-back stimulation cycles with oral contraceptives or progestins in women undergoing embryo accumulation for preimplantation genetic testing, a retrospective study. Gynecological Endocrinology, 2018, 34, 955-960.	0.7	4
103	Intracytoplasmic sperm injection for all or for a few?. Fertility and Sterility, 2022, 117, 270-284.	0.5	4
104	Progesterone-primed ovarian stimulation in oocyte donation: a model for elective fertility preservation?. Reproductive BioMedicine Online, 2022, 44, 1015-1022.	1.1	4
105	General infertility workup in times of high assisted reproductive technology efficacy. Fertility and Sterility, 2022, 118, 8-18.	0.5	4
106	Screening practice and misplaced priorities. Clinical and Translational Oncology, 2009, 11, 228-236.	1.2	3
107	Guidelines on Chemotherapy in Advanced Stage Gynecological Malignancies: An Evaluation of 224 Professional Societies and Organizations. PLoS ONE, 2011, 6, e20106.	1.1	3
108	Combined Vitamin C and E supplementation for Preeclampsia: No Significant Effect But Significant Heterogeneity?. Hypertension in Pregnancy, 2012, 31, 375-376.	0.5	3

#	Article	IF	Citations
109	AMH for predicting poor ovarian responders in GnRH antagonist cycles. Human Reproduction, 2012, 27, 1876-1877.	0.4	3
110	EStradiol and PRogesterone in In vitro ferTilization (ESPRIT): a multicenter study evaluating third-versus second-generation estradiol and progesterone immunoassays. Journal of Endocrinological Investigation, 2020, 43, 1239-1248.	1.8	3
111	The effect of trophectoderm biopsy technique and sample handling on artefactual mosaicism. Journal of Assisted Reproduction and Genetics, 2022, 39, 1333-1340.	1.2	3
112	Low Colorectal Cancer Screening Rates and Primary Care Physicians' Behavior. American Journal of Gastroenterology, 2008, 103, 804-805.	0.2	2
113	The Cost of Therapy Services Provided by a Day Psychotherapy Unit. Group Analysis, 2012, 45, 515-535.	0.2	2
114	Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study. Frontiers in Endocrinology, 2019, 10, 115.	1.5	2
115	Ultrasonographically diagnosed dermoid cysts do not influence ovarian stimulation response in an <i>iin vitro</i> iii fertilization cycle. Gynecological Endocrinology, 2019, 35, 612-617.	0.7	2
116	Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. Journal of the National Cancer Institute, 2007, 99, 176-177.	3.0	1
117	Reply: Is it necessary to recognize the sub-optimal responder. Human Reproduction, 2015, 30, dev255.	0.4	1
118	Vitamin D and ovarian reserve: making clinical decisions. Human Reproduction, 2017, 32, 1138-1139.	0.4	1
119	Androgens and Anti-Mýllerian Hormone in Infertile Patients. Reproductive Sciences, 2021, 28, 2816-2821.	1.1	1
120	The Impact of Elevated Progesterone on the Initiation of an Artificially Prepared Frozen Embryo Transfer Cycle: A Case Series. Current Pharmaceutical Biotechnology, 2017, 18, 619-621.	0.9	1
121	Reply: Rapid changes in practice make analysis of historical databases irrelevant for contemporary counselling. Human Reproduction, 2017, 32, 1-2.	0.4	0
122	Evaluation and ART of the Low Ovarian Responder Patient. , 2018, , 299-303.		0
123	Reply: Individualized luteal phase support in artificially prepared frozen embryo transfer cycles based on serum progesterone levels: a prospective cohort study. Human Reproduction, 2021, 36, 2623-2624.	0.4	0
124	Effect of BRCA mutation on prognosis in patients with ovarian cancer: A systematic review and meta-analysis Journal of Clinical Oncology, 2012, 30, 5066-5066.	0.8	0
125	Cardiac toxicity in breast cancer patients treated with dual HER2 blockade: A meta-analysis of randomized evidence Journal of Clinical Oncology, 2013, 31, 624-624.	0.8	0